NeuroBo Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

NeuroBo Pharmaceuticals CEO'su Hyung-Heon Kim, Aug2023 tarihinde atandı, in görev süresi 1.25 yıldır. in toplam yıllık tazminatı $ 1.01M olup, şirket hissesi ve opsiyonları dahil olmak üzere 17.2% maaş ve 82.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.32% ine doğrudan sahiptir ve bu hisseler $ 64.86K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.3 yıl ve 3.3 yıldır.

Anahtar bilgiler

Hyung-Heon Kim

İcra Kurulu Başkanı

US$1.0m

Toplam tazminat

CEO maaş yüzdesi	17.2%
CEO görev süresi	1.3yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	1.3yrs
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation

Oct 03

NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Sep 29

Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely

Sep 14

NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split

Sep 12

NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases

Nov 25

NeuroBo on track to post a record gain after announcing a special meeting

Jun 14

NeuroBo Pharmaceuticals rallies on ANA Therapeutics acquisition

Jan 06

Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like

Dec 21

NeuroBo Pharmaceuticals EPS misses by $0.02

Nov 13

CEO Tazminat Analizi

Hyung-Heon Kim'un ücretlendirmesi NeuroBo Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$28m
Jun 30 2024	n/a	n/a	-US$26m
Mar 31 2024	n/a	n/a	-US$17m
Dec 31 2023	US$1m	US$174k	-US$12m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	n/a	n/a	-US$11m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$61k	n/a	-US$14m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	-US$14m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$29k	n/a	-US$15m

Tazminat ve Piyasa: Hyung-Heon 'nin toplam tazminatı ($USD 1.01M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 650.80K ).

Tazminat ve Kazançlar: Hyung-Heon şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Hyung-Heon Kim (49 yo)

1.3yrs

Görev süresi

US$1,012,073

Tazminat

Mr. Hyung-Heon Kim had been Independent Director of NeuroBo Pharmaceuticals, Inc. since July 09, 2021 until August 11, 2023 and serves as its Chief Executive Officer, President of NeuroBo Pharmaceuticals,...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hyung-Heon Kim	CEO, President & Director	1.3yrs	US$1.01m	0.32% $ 64.9k
Marshall Woodworth	Chief Financial Officer	1.1yrs	US$154.50k	Veri yok
Mi-Kyung Kim	Chief Scientific Officer	1.3yrs	Veri yok	Veri yok
Robert Homolka	Senior Vice President of Clinical Operations	1.3yrs	Veri yok	Veri yok

1.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim: NRBO 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hyung-Heon Kim	CEO, President & Director	3.3yrs	US$1.01m	0.32% $ 64.9k
D. Strickland	Independent Director	2.8yrs	US$110.71k	0.11% $ 23.0k
Andrew Koven	Independent Chairman of the Board	3.3yrs	US$140.84k	0.11% $ 23.0k
Michael Salsbury	Independent Director	4.9yrs	US$102.36k	0.11% $ 23.0k
Roy Freeman	Chairman of Scientific Advisory Board	no data	Veri yok	Veri yok
Mark Glickman	Independent Director	1.5yrs	US$50.47k	0.045% $ 9.2k
Caroline Apovian	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jason Groves	Independent Director	4.9yrs	US$100.35k	0.11% $ 23.0k
James Tursi	Independent Director	less than a year	US$21.93k	0.029% $ 5.8k
Leigh Perreault	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

62.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NRBO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

NeuroBo Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2024

NeuroBo Pharmaceuticals, Inc. Appoints James P. Tursi to its Board of Directors and as Member of Nominating and Corporate Governance Committee

NeuroBo Pharmaceuticals, Inc. Appoints Marshall H. Woodworth as Acting Chief Financial Officer

NeuroBo Pharmaceuticals, Inc. Announces Resignation of Na Yeon (Irene) Kim from the Board of Directors

NeuroBo Pharmaceuticals, Inc. Announces Executive Changes

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 28, 2023

Recent updates

New major risk - Financial position

NeuroBo Pharmaceuticals, Inc. Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation

Neurobo Pharmaceuticals Announces Positive Top-Line Data from the Sad Part 1 of Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. announced that it has received $17.000005 million in funding from Dong-A ST Co., Ltd.

NeuroBo Pharmaceuticals, Inc. Doses First Patient in the MAD Part 2 of its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3.000001 million.

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2024

NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals, Inc. Receives Safety Review Committee Approval to Continue with Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment

Neurobo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of Da-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2A Clinical Trial Evaluating Da-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. Appoints James P. Tursi to its Board of Directors and as Member of Nominating and Corporate Governance Committee

NeuroBo Pharmaceuticals, Inc. Appoints Marshall H. Woodworth as Acting Chief Financial Officer

NeuroBo Pharmaceuticals, Inc. Announces Resignation of Na Yeon (Irene) Kim from the Board of Directors

NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of Nash

NeuroBo Pharmaceuticals, Inc. Announces Executive Changes

NeuroBo Pharmaceuticals Receives 180-Day Extension to February 5, 2024 from Nasdaq to Regain Compliance with the Minimum Bid Price Requirement

Neurobo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of NASH

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 28, 2023

Neurobo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to Its Board of Directors

NeuroBo Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

NeuroBo Pharmaceuticals, Inc. Appoints Joseph Hooker as President

NeuroBo Pharmaceuticals, Inc. announced that it has received $15 million in funding from Dong-A ST Co., Ltd.

NeuroBo Pharmaceuticals Compliant with All Applicable Nasdaq Listing Criteria

NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $37 million in funding from Dong-A ST Co., Ltd.

Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely

NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2022

Neurobo Pharmaceuticals, Inc. Appoints Matthew Bardin as Senior Vice President Operations

High number of new and inexperienced directors

NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors

NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases

No longer forecast to breakeven

Independent Director Jeong Gyun Oh has left the company

No longer forecast to breakeven

Price target decreased to US$16.00

NeuroBo Pharmaceuticals, Inc.(NasdaqCM:NRBO) dropped from Russell 3000E Index

NeuroBo on track to post a record gain after announcing a special meeting

NeuroBo Pharmaceuticals, Inc. announced delayed annual 10-K filing

NeuroBo Pharmaceuticals, Inc. Announces Board Changes

New 90-day low: US$4.68

NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding

Neurobo Pharmaceuticals, Inc. Announces Executive Changes

Neurobo Pharmaceuticals, Inc. Appoints Akash Bakshi as Class II Director to the Board and Chief Operating Officer and Senior Vice President

New 90-day high: US$6.68

NeuroBo Pharmaceuticals rallies on ANA Therapeutics acquisition

Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like

NeuroBo Pharmaceuticals EPS misses by $0.02

New 90-day low: US$5.24

New 90-day low - US$5.80

New 90-day low - US$6.16

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş